Description

Orexin B 5mg – Hypocretin-2 Neuropeptide Research

Orexin B 5mg is a research product designation for orexin-B, also known as hypocretin-2, a naturally occurring 28-amino-acid neuropeptide involved in the regulation of wakefulness, arousal, sleep–wake transitions and energy-related signalling.

Orexin B is produced from the precursor protein prepro-orexin, encoded by the HCRT gene. It belongs to the orexin neuropeptide system, which includes orexin-A and two principal G-protein-coupled receptors: orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R).

Scientific investigations have examined orexin-B in relation to hypothalamic signalling, receptor activation, neuronal excitability, sleep regulation and metabolic physiology. Research into the broader orexin system has also contributed to understanding narcolepsy and the development of medicines targeting orexin receptors.

Orexin B 5mg is intended for controlled laboratory research. Its use as a treatment for sleep disorders, obesity, fatigue or other human conditions has not been established.

What Is Orexin B 5mg?

Orexin B 5mg refers to a product labelled as containing 5mg of the neuropeptide orexin-B.

Orexin-B, also called hypocretin-2, is a peptide produced through processing of the prepro-orexin precursor.

The mature peptide contains 28 amino acid residues and has a C-terminal amide group.

It is associated with hypothalamic neurons that project to multiple regions of the central nervous system.

These neuronal networks participate in regulating wakefulness, arousal, behavioural state and physiological responses to energy availability.

Orexin B should not be confused with orexin receptor antagonists, which are pharmaceutical compounds designed to block orexin signalling.

Orexin B 5mg Product Specifications

• Product Name: Orexin B 5mg
• Scientific Name: Orexin-B
• Alternative Name: Hypocretin-2
• Classification: Endogenous neuropeptide
• Peptide Family: Orexin/hypocretin
• Peptide Length: 28 amino acid residues
• Reference Sequence: RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2
• Reference Molecular Formula: C123H212N44O35
• Reference Molecular Weight: Approximately 2,899.3 g/mol
• Commonly Listed CAS Number: 205640-90-0
• Precursor Protein: Prepro-orexin
• Associated Gene: HCRT
• Primary Receptors: OX1R and OX2R
• Receptor Classification: G-protein-coupled receptors
• Primary Research Focus: Sleep–wake and arousal signalling
• Additional Research Focus: Neuronal excitability and energy-related signalling
• Labelled Quantity: 5mg
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

These specifications describe the commonly referenced human orexin-B peptide. Product identity, salt form, purity, actual peptide content and physical presentation should be verified using batch-specific manufacturer documentation.

Orexin B Amino Acid Sequence and Molecular Structure

Human orexin-B is a 28-amino-acid peptide with a C-terminal amide.

Its reference sequence is:

RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2

Unlike orexin-A, orexin-B does not contain intramolecular disulfide bonds.

The mature peptide is generated from a larger precursor protein through biological processing.

The C-terminal amidation is an important structural feature and should be included when verifying the identity of a research preparation.

Researchers should confirm whether the supplied product corresponds to the amidated human sequence rather than a non-amidated or species-specific analogue.

How Does Orexin B Work?

Orexin B participates in signalling through the orexin receptor system.

The two principal receptors are orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R).

Both are G-protein-coupled receptors involved in neuronal signalling.

Orexin-B generally shows greater functional activity at OX2R than at OX1R in many experimental systems, whereas orexin-A activates both receptor subtypes with relatively high potency.

Activation of orexin receptors can influence intracellular signalling, neuronal excitability and communication between brain regions involved in arousal.

However, receptor pharmacology varies with experimental conditions and cellular context.

Laboratory receptor activity does not establish the effectiveness of administering orexin-B as a human treatment.

Scientific Research Into Orexin B 5mg

1. Orexin B 5mg and Sleep–Wake Regulation

The sleep–wake cycle is regulated by interacting networks of neurons and neurotransmitters.

Orexin neurons are important components of the brain’s wakefulness-promoting circuitry.

Orexin-B has been investigated as one of the endogenous signalling molecules participating in these networks.

Studies of the orexin system demonstrate its importance in stabilising transitions between wakefulness and sleep.

However, these findings do not establish that Orexin B 5mg is an effective human wakefulness treatment.

2. Orexin B and Hypocretin-2 Research

Orexin-B and hypocretin-2 are names for the same mature neuropeptide.

The orexin and hypocretin naming systems arose from separate discoveries of the same neuropeptide family.

Researchers commonly use both terms in neuroscience literature.

Hypocretin-2 should not be confused with the HCRTR2 gene, which encodes the orexin receptor type 2.

3. Orexin B 5mg and OX2R Signalling

Orexin receptor type 2 is a G-protein-coupled receptor involved in arousal regulation.

Orexin-B has been investigated for its ability to activate OX2R in experimental systems.

OX2R is an important target in research into sleep disorders and wakefulness regulation.

However, receptor activation in laboratory experiments does not establish safe or effective human treatment with orexin-B peptide.

4. Orexin B and OX1R Research

Orexin receptor type 1 is another receptor within the orexin signalling system.

Orexin-B can activate OX1R, although its relative potency is generally lower than at OX2R in commonly studied systems.

Researchers use receptor-binding and functional assays to examine these differences.

The resulting findings contribute to understanding receptor subtype selectivity.

5. Orexin B 5mg and Hypothalamic Research

The hypothalamus coordinates multiple physiological processes, including sleep, arousal, feeding and endocrine regulation.

Orexin-producing neurons are concentrated in regions of the lateral and posterior hypothalamus.

These neurons project widely throughout the central nervous system.

Orexin-B research contributes to understanding how hypothalamic signals influence distributed neuronal networks.

6. Orexin B and Neuronal Excitability

Neuronal excitability describes the ability of neurons to respond to signals and generate electrical activity.

Orexin receptor activation can influence neuronal excitability through intracellular signalling mechanisms.

Experimental studies have examined orexin-related responses in multiple neuronal populations.

However, the resulting effects depend on receptor expression, brain region and experimental conditions.

7. Orexin B 5mg and Narcolepsy Research

Narcolepsy type 1 is strongly associated with loss of orexin-producing neurons and deficiency of orexin signalling.

Research into orexin peptides and receptors has helped clarify the biological mechanisms underlying this disorder.

Orexin-B is one of the endogenous peptides involved in the broader system.

However, a deficiency in orexin signalling does not establish that a commercial orexin-B peptide preparation is an effective treatment.

Investigational receptor agonists and other therapeutic approaches must be evaluated separately.

8. Orexin B and Orexin Receptor Antagonists

Orexin receptor antagonists block orexin signalling.

Some dual orexin receptor antagonists have been developed and approved for insomnia in certain jurisdictions.

Orexin-B is a naturally occurring receptor agonist rather than an antagonist.

Therefore, the mechanism and clinical evidence for orexin receptor antagonists should not be attributed to orexin-B peptide.

9. Orexin B 5mg and Energy Homeostasis

Energy homeostasis describes the regulation of energy intake, expenditure and availability.

Orexin neurons respond to signals associated with metabolic state.

Experimental research has investigated relationships between orexin signalling, feeding behaviour and energy expenditure.

However, these relationships are complex and vary with physiological context.

They do not establish that Orexin B 5mg safely reduces body weight in humans.

10. Orexin B and Feeding Behaviour Research

Orexin peptides were initially identified partly through investigations of feeding-related signalling.

Animal studies have examined the effects of orexin-related pathways on food intake.

However, feeding behaviour is influenced by many interacting neural and hormonal systems.

Findings involving orexin-A, orexin-B or receptor-specific compounds should not be treated as interchangeable.

11. Orexin B 5mg and Reward Circuitry

Orexin signalling has been investigated in brain circuits involved in motivation and reward.

These systems interact with arousal and behavioural state regulation.

Research involving orexin receptors has explored responses to rewarding stimuli and environmental cues.

However, the precise contribution of orexin-B depends on the experimental model.

12. Orexin B and Stress-Related Signalling

Stress responses involve interactions among neural circuits, autonomic pathways and endocrine systems.

Orexin signalling participates in several of these networks.

Researchers have examined orexin-related effects on arousal and stress-associated physiological responses.

However, these observations do not establish a therapeutic role for Orexin B 5mg in anxiety or stress disorders.

13. Orexin B 5mg and Circadian Biology

Circadian rhythms influence daily patterns of sleep, activity and hormone secretion.

The orexin system interacts with neural networks involved in maintaining wakefulness across the day.

However, orexin-B is not itself the central circadian clock.

Researchers distinguish circadian timing from the neural mechanisms that stabilise wakefulness.

14. Orexin B and Receptor Pharmacology

Receptor pharmacology investigates how signalling molecules interact with their biological targets.

Orexin-B has been used in laboratory research examining OX1R and OX2R.

Researchers can compare receptor affinity, functional potency and downstream signalling responses.

These studies support understanding of the orexin system and development of receptor-targeted compounds.

15. Orexin B 5mg and Research Reproducibility

Reliable neuropeptide research requires accurately characterised materials.

Researchers should verify the complete 28-residue sequence and C-terminal amidation.

Differences in salt form, peptide purity, oxidation and formulation can influence experimental results.

Batch-specific analytical documentation is important for reproducibility.

Orexin B 5mg vs Orexin A

Orexin-A and orexin-B are distinct peptides derived from the same precursor protein.

• • Orexin B: Contains 28 amino acid residues.
  • Orexin A: Contains 33 amino acid residues.
  • Disulfide Bonds: Orexin-A contains two intramolecular disulfide bonds; orexin-B does not.
  • Receptor Activity: Orexin-B generally shows greater relative potency at OX2R, while orexin-A is a potent agonist at both OX1R and OX2R.
  • Reference Molecular Formula: C123H212N44O35S

Findings involving one peptide should not automatically be attributed to the other.

Orexin B 5mg vs Orexin Receptor Agonists

Orexin-B is an endogenous peptide ligand of orexin receptors.

Experimental orexin receptor agonists may have different chemical structures and pharmacokinetic properties.

Some investigational compounds are designed to target OX2R selectively.

However, evidence involving a particular investigational agonist cannot establish the clinical effectiveness of Orexin B 5mg.

Orexin B 5mg vs Orexin Receptor Antagonists

Orexin receptor antagonists reduce signalling through orexin receptors.

They are pharmacologically different from orexin-B, which activates these receptors.

Clinical evidence for insomnia medicines that block orexin signalling should not be used to support claims about orexin-B peptide.

Orexin B 5mg and Weight-Loss Claims

Orexin signalling has been investigated in relation to energy balance and feeding behaviour.

However, the relationship between orexin signalling and body weight is complex.

There is insufficient reliable human clinical evidence demonstrating that Orexin B 5mg safely reduces body fat or treats obesity.

It should not be marketed as a proven weight-loss peptide.

Orexin B 5mg and Wakefulness Claims

The orexin system plays a central role in wakefulness regulation.

However, this does not establish that Orexin B 5mg is an effective or safe treatment for excessive daytime sleepiness.

Peptide delivery, receptor activation, tissue distribution and clinical safety require separate investigation.

Orexin-B should not be presented as an approved alternative to established sleep disorder treatments.

Orexin B 5mg Research Quality and Documentation

Important considerations when evaluating Orexin B 5mg research material include:

• Verification of the complete 28-amino-acid sequence
• Confirmation of C-terminal amidation
• Verification of the expected molecular mass
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 5mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Documentation of formulation components
• Product-specific storage and stability information
• Clearly stated research-use classification

Storage and Handling of Orexin B 5mg

Orexin B 5mg should be stored according to verified manufacturer instructions.

Storage requirements depend on peptide formulation, salt form, packaging and stability characteristics.

Researchers should not assume that all orexin-B preparations have identical storage requirements or shelf lives.

Laboratory handling should follow institutional procedures and product-specific safety documentation.

Orexin B 5mg Safety and Scientific Limitations

Orexin B 5mg is a research material without an established human therapeutic safety or effectiveness profile.

Important uncertainties include pharmacokinetics, central nervous system exposure, unintended receptor activity and the effects of repeated exposure.

Because orexin signalling participates in arousal, autonomic function and other physiological processes, altering this system may produce effects beyond wakefulness alone.

There is insufficient reliable evidence demonstrating safe and effective human use for weight loss, fatigue, narcolepsy or cognitive enhancement.

Orexin-B is not an established approved UK medicine for these purposes.

Research-grade material should not be assumed suitable for human administration.

The labelled 5mg quantity is not a human dosing recommendation.

Frequently Asked Questions About Orexin B 5mg

What is Orexin B 5mg?

Orexin B 5mg is a product designation for the 28-amino-acid neuropeptide orexin-B, also called hypocretin-2, with a labelled quantity of 5mg.

What is another name for Orexin B?

Orexin-B is also known as hypocretin-2.

How many amino acids does Orexin B contain?

Human orexin-B contains 28 amino acid residues.

What is the Orexin B peptide sequence?

The reference sequence is RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2.

What is the molecular weight of Orexin B?

The reference molecular weight is approximately 2,899.3 g/mol.

What is the CAS number for Orexin B?

A commonly listed CAS number is 205640-90-0.

Is Orexin B the same as Orexin A?

No. Orexin-B contains 28 amino acids, while orexin-A contains 33 amino acids and two disulfide bonds.

Which receptors does Orexin B activate?

Orexin-B activates orexin receptors OX1R and OX2R, generally showing greater relative potency at OX2R.

Is Orexin B involved in sleep regulation?

Yes. The orexin system is important in regulating wakefulness and stabilising sleep–wake transitions.

Is Orexin B a treatment for narcolepsy?

No. Orexin-B peptide is not an established approved treatment for narcolepsy.

Does Orexin B help with weight loss?

There is insufficient reliable human clinical evidence demonstrating that Orexin B safely produces weight loss.

Is Orexin B approved for human use?

Orexin-B is not an established approved UK medicine for sleep disorders, weight management or cognitive enhancement.

What does Orexin B 5mg mean?

The designation refers to a labelled quantity of 5mg of research material, not a recommended human dose.

Orexin B 5mg – Scientific Product Summary

Orexin B 5mg is a research product designation for the endogenous 28-amino-acid neuropeptide orexin-B, also known as hypocretin-2.

It is derived from prepro-orexin and participates in signalling through the orexin receptor system.

Published research has investigated orexin-B in relation to OX1R and OX2R activity, sleep–wake regulation, hypothalamic signalling, neuronal excitability and energy homeostasis.

However, these scientific findings do not establish human therapeutic effectiveness or long-term safety.

Researchers evaluating Orexin B 5mg should verify molecular identity, C-terminal amidation, purity, formulation, labelled quantity and batch-specific analytical documentation.